Experiences with leflunomide in solid organ transplantation.
about
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytesThe active metabolite of leflunomide, A77 1726, interferes with dendritic cell functionLeflunomide: a drug with a potential beyond rheumatologyAntiviral drug resistance of human cytomegalovirus.Critical care aspects of lung transplantation.Immunosuppression for lung transplantation.A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.Sjogren's syndrome: evolving therapies.Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis.Emergent role of gasotransmitters in ischemia-reperfusion injury.Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.Developments in liver transplantation.Current and future immunosuppressive strategies in renal transplantation.Immunosuppression: towards a logical approach in liver transplantation.Immunosuppression for heart transplantation: where are we now?Polyomavirus-associated nephropathy: update on antiviral strategies.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Chronic Diarrhea Associated with High Teriflunomide Blood ConcentrationUse of leflunomide in the treatment of polyomavirus BK-associated nephropathy.Leflunomide in renal transplantation.Leflunomide for cytomegalovirus: bench to bedside.Safety evaluation of leflunomide in rheumatoid arthritis.The human polyomavirus BK (BKPyV): virological background and clinical implications.Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient.Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy.Effect of leflunomide on immunological liver injury in mice.Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy.Leflunomide in the treatment of rheumatoid arthritis.Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells.Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction.A child with BK virus infection: inadequacy of current therapeutic strategies.The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.Efficacy and safety of leflunomide for the treatment of BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
P2860
Q24800491-770E83D8-A757-4D43-B93E-A3CC5748176AQ24816880-D56D50B6-80A3-4441-B224-30E4427C72B8Q28294236-1CFAF749-58C6-400F-97B8-FFB47878A735Q30430427-79457ABE-0D4E-49A0-B33B-2C04F4BEF738Q33360317-1ACA935F-4D42-4754-83D9-BC562B2EB9E9Q33996931-BE6D5E4C-1956-4056-B642-AD0BA5A27354Q34352832-685CF06B-9FA0-435A-96CA-F532815CA5E9Q35015845-26FB0A77-9281-4681-86A1-677D374F754DQ35056070-BE446802-4AEF-4737-B5EA-2E8CA1578FE9Q35091815-C4F945BA-6ADF-46DB-B0F1-1ED286F03875Q35321111-BF16DF59-59A4-4ADF-8B0E-8B26134CC2F7Q35555376-FCBD0153-DC0E-4042-91AB-50009A7FDC9FQ35592509-46801C50-CEAC-4F99-9DC3-119F00E3BD64Q35596527-1EA3365C-3464-46DD-B3A6-9CEC1AB8C8B0Q35906315-00808ED2-FC26-4C52-AB9B-64C06F8D86B3Q35987954-D485799D-1785-4212-BFB5-33739904B93FQ36433573-0CC7BECB-3A58-4DE6-9167-65C998EC465EQ36492418-B0394E64-B6B5-4E00-932F-D2F7456FD1ACQ37064446-6C80AFBF-A337-48AF-9252-0DBC9BA779A0Q37208447-FF618083-6208-42AF-9AF8-83420FB415FFQ37310698-A868FC15-1E74-4DBA-B74F-6728FD28C6F8Q37877256-D08DD4A3-3B59-43B5-9E8C-4038682B5E50Q37957446-C97B45E9-0050-47B2-96D3-70E3A1697748Q38106213-BD3EAA3A-C877-467C-BE19-D0A88BCCE989Q38115582-3070467C-0BA1-47A2-9124-5BB224C2DE27Q38168278-75DB10C3-C664-4574-833A-795D61EBB3CAQ38725677-421B301C-5395-48A9-B4C4-693674EFB8D9Q40259798-0943B1D1-3669-437B-91FF-0752E7E52162Q40329754-A72B7806-DC07-4AE4-AE8A-FD9DF6C96100Q41781500-5CF0CA84-776C-4EB2-B088-2722A69FC4E7Q42268339-F4C123CF-BB62-4785-9864-BCD7EE5D0FE8Q43061691-174518A2-CFE5-4AC3-A205-83901BCFF64CQ43248290-7CB17AC0-7532-4FD5-A748-A5E0BF3EB793Q43749375-B8C7A514-52CC-48B8-8CE4-0B058BFA9690Q43754050-471802BF-8E07-4077-A904-CC5C5BD01755Q44800322-EFDDAE79-8297-434E-9A94-CE5A106C41D6Q45111047-773B2CC1-4647-4CFD-9BFC-B9815BE47719Q45352497-7A99139B-742B-42EE-8A66-592FD9918DF1Q46909270-9A06C2B6-C04A-4635-BC81-457AAF67903CQ46936046-666952B3-0324-42DC-8CDD-2F904D8D9D23
P2860
Experiences with leflunomide in solid organ transplantation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Experiences with leflunomide in solid organ transplantation.
@ast
Experiences with leflunomide in solid organ transplantation.
@en
Experiences with leflunomide in solid organ transplantation.
@nl
type
label
Experiences with leflunomide in solid organ transplantation.
@ast
Experiences with leflunomide in solid organ transplantation.
@en
Experiences with leflunomide in solid organ transplantation.
@nl
prefLabel
Experiences with leflunomide in solid organ transplantation.
@ast
Experiences with leflunomide in solid organ transplantation.
@en
Experiences with leflunomide in solid organ transplantation.
@nl
P2093
P1433
P1476
Experiences with leflunomide in solid organ transplantation.
@en
P2093
Anita Chong
Anita Kottayil
Deepak Mital
James Longstreth
James W Williams
Lynda Brady
Michael Millis
Stephen Jensik
Wanyun Huang
P304
P356
10.1097/00007890-200202150-00008
P577
2002-02-01T00:00:00Z